LobbyingAmneal Pharmaceuticals lobbying by quarter
Amneal Pharmaceuticals AMRX's latest lobbying report covers Q2 2026, at $270K. The four quarters Q4 2025–Q3 2026 total $960K. Its first report covers Q1 2024; the issues it reports most are Health Issues and Manufacturing.
Amneal PharmaceuticalsAMRX
- Latest quarter
- No record
- Q3 2026 · 0 reports
- Last 12 months
- $960K
- Last 4 quarters
- vs last quarter
- −100.0%
- Q3 2026 against the quarter before
- First report
- Q1 2024
- The first quarter a report named it
Lobbying by quarter
| Quarter | Amount | Reports |
|---|---|---|
| Q1 2024 | $910K | 2 |
| Q2 2024 | $300K | 2 |
| Q3 2024 | $290K | 2 |
| Q4 2024 | $270K | 2 |
| Q1 2025 | $990K | 3 |
| Q2 2025 | $290K | 3 |
| Q3 2025 | $390K | 3 |
| Q4 2025 | $420K | 3 |
| Q1 2026 | $270K | 3 |
| Q2 2026 | $270K | 3 |
| Q3 2026 | $0 | 0 |
By issue
- Health issues$4.2M · 20 reports
- Manufacturing$120K · 6 reports
- Budget and appropriations$60K · 2 reports
An issue's amount splits each report's amount equally over the issues the report lists.
Who was lobbied
- HOUSE OF REPRESENTATIVES26 reports
- SENATE26 reports
- White House Office6 reports
Firms it paid
| Firm | ||
|---|---|---|
| In-houseAmneal Pharmaceuticals | $3.7M | 10 quarters |
| Tarplin, Downs & Young | $600K | 10 quarters |
| Ogr | $120K | 6 quarters |
Former officials lobbying for it
| Former position | ||
|---|---|---|
| CHARLOTTE SPEARS IVANCIC | Leg. Counsel, Sen. Jim DeMint; Health Counsel, Maj. Leader Bill Frist; Counsel and Budget Analyst, House Budget Cmte.; Asst. to the Speaker for Policy, Speaker John Boehner | Q2 2026 |
| ELIZABETH T MURRAY | Senior Policy Advisor, Democratic Whip Steny Hoyer; Leg. Asst., Rep. Mike Thompson, Rep. Bob Matsui, and Sen. Bob Graham | Q2 2026 |
| EMILY H MURRY | Staff Dir., Sub. Cmte. on Helath, Ways and Means Cmte; Sr. Policy Adivsor, Maj. Leader McCarthy; Policy Advisor, Maj. Whip McCarthy; Prof. Staff, Republicans Study Cmte.; Leg. Aide, Rep. Ken Calvert; Leg. Asst., Rep. Tom Price | Q2 2026 |
| JEFF RECZEK | Dir. CDC Washington, Professional Staff Sen. Appropriations Cmte, Program Examiner OMB, Program Analyst Dept. of Transportation | Q2 2026 |
| JENNIFER B YOUNG | Asst. Sec. for Leg.- HHS; Dep. Asst. Sec for Leg. - HHS; Cmte. Staff, House Cmte. on Ways and Means; Cmte. Staff. Sen. Cmte. on Finance | Q2 2026 |
| MARGARET JOSEPH | CoS for Sen. Kyrsten Sinema, CoS for Rep. Kyrsten Sinema, CoS for Rep. Bobby Bright, CoS for Rep. Jim Matheson, Clerk for House Rules Cmte. | Q2 2026 |
| PAMELA SMITH | Leg. Dir., Sen. Tom Harkin; Dep. Staff Dir., Sen. HELP Cmte.; Staff Dir., Sen. HELP Cmte.; Counsel to Asst. AG, Civil Div., Dept. of Justice; Spec. Counsel, Ofc of Leg. Affairs, Dept. of Justice; Counsel and LA, Sen. Carol Moseley-Braun | Q2 2026 |
| PARICK BRAERTON CARROLL | Leg Asst. Rep. Ray LaHood, Leg Dir. Rep. Kevin Yoder, PSM Senate Appropriations Cmte. | Q2 2026 |
| PETER FISE | Health Counsel for Sen. Cmte on Finance, Health Counsel for Sen. Jeanne Shaheen, Staff Assistant for House Cmte on Oversight & Government Reform | Q2 2026 |
| RAISSA H DOWNS | Prin. Dep. Asst. Sec for Leg.-HHS; Dep. Asst. Sec. for Leg.-HSS; Staff Dir., Sub Cmte. on Employment, Sen. HELP Cmte. | Q2 2026 |
| LAURA FRIEDEL | Leg. Asst., Sen. Zell Miller, Leg. Dir., Sen. Richard Shelby, Clerk, Staff Dir., Sen. Appropriations Committee | Q3 2025 |
| KIMBERLY LYNN BRANDT | Sr. Counsel and Dir. External Affairs - HHS OIG; Prin. Dep. Administrator for Policy and Operations, and Dir. of Medicare Program Integrity - CMS; Chief Oversight and General Counsel, Sen. Cmte. on Finance | Q4 2024 |
Lobbying reports
| Filed by | ||
|---|---|---|
| 07/20for Q2 | In-house | $190K |
| 07/17for Q2 | Ogr | $20K |
| 07/16for Q2 | Tarplin, Downs & Young | $60K |
| 04/20for Q1 | In-house | $190K |
| 04/20for Q1 | Tarplin, Downs & Young | $60K |
| 04/19for Q1 | Ogr | $20K |
| 01/20for Q4 2025 | Tarplin, Downs & Young | $60K |
| 01/20for Q4 2025 | In-house | $340K |
| 01/17for Q4 2025 | Ogr | $20K |
| 25/10/20for Q3 2025 | In-house | $310K |
| 25/10/19for Q3 2025 | Ogr | $20K |
| 25/10/16for Q3 2025 | Tarplin, Downs & Young | $60K |
| 25/07/21for Q2 2025 | In-house | $210K |
| 25/07/19for Q2 2025 | Ogr | $20K |
| 25/07/16for Q2 2025 | Tarplin, Downs & Young | $60K |
| 25/04/21for Q1 2025 | In-house | $910K |
| 25/04/21for Q1 2025 | Ogr | $20K |
| 25/04/15for Q1 2025 | Tarplin, Downs & Young | $60K |
| 25/02/14for Q1 2025 | Ogr | Under $5,000 |
| 25/01/21for Q4 2024 | Tarplin, Downs & Young | $60K |